



Novel HIV Immunization Regimens and Immune Implications

Guest Editors:

Dr. Hongying Duan

Vaccine Research Center,
National Institutes of Health,
Bethesda, MD 20892, USA

Dr. Rui Kong

Emory Vaccine Center, Emory
University School of Medicine,
Atlanta, GA 30322, USA

Deadline for manuscript
submissions:

30 November 2024

Message from the Guest Editors

The elicitation of a protective immune response is the goal of vaccine research for HIV-1 and other pathogens. Novel vaccine platforms, such as nanoparticles, virus-like particles (VLPs), and mRNA LNP platforms, combined with new adjuvants and immunization regimens, have provided promising approaches to vaccine development for emerging disease pathogens and for difficult-to-achieve vaccines. Understanding the implication of vaccine-elicited immune response with these new immunogens/regimens will move the field forward and help the evaluation and development of more effective vaccine products.

Manuscripts reporting on new HIV-1 immunogens, novel immunization regimens, immune response analysis with new antigens and methods, immune response monitoring, and new animal models are welcome for this Special Issue.

This Special Issue encourages the submission of original articles, systematic reviews, meta-analyses, short communications, and other types of articles that describe the application of new immunogens and immunization regimens, or the association of immune responses to vaccine outcomes.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com